MACSprep Multiple Myeloma CD138 MicroBeads have been developed for the positive selection of CD138+ cells directly from anticoagulated whole blood or bone marrow by using the autoMACS® Pro Separator or manual separators without additional density gradient centrifugation nor erythrocyte lysis. The purified CD138+ cells are well suited for further flow cytometry, functional, or molecular analysis such as FISH, PCR, sequencing, microarrays, and protein analysis.
Separation of a bone marrow sample using MACSprep™ Multiple Myeloma CD138 MicroBeads and the autoMACS® Pro Separator. Cells were fluorescently stained with CD138-APC, CD38-FITC, and CD45-VioBlue® and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
MACSprep Multiple Myeloma CD138 MicroBeads have been developed for the positive selection of CD138+ cells directly from anticoagulated whole blood or bone marrow by using the autoMACS® Pro Separator or manual separators without additional density gradient centrifugation nor erythrocyte lysis. The purified CD138+ cells are well suited for further flow cytometry, functional, or molecular analysis such as FISH, PCR, sequencing, microarrays, and protein analysis.
- Sato, T. et al. (2019) DPP8 is a novel therapeutic target for multiple myeloma. Sci Rep 9 (1): 18094
- Isa, R. et al. (2022) The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. Int J Mol Sci 23 (6): 2919
You have previously chosen International as your location.
What do you want to do?